V-INTERVENTIONNCT06909565
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 34 versions: 34 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Trial sites expanded: 149 → 153 locations
- Minor Trial sites expanded: 145 → 149 locations
- Minor Trial sites expanded: 142 → 145 locations
- Minor Study sites: 142 to 145
- Minor Study sites: 141 to 142
Show 3 earlier versionsHide 3 earlier versions
- Minor Study sites: 139 to 141
- Minor Study sites: 138 to 139
- Notable Eligibility criteria expanded, about 12 words
- Study sites: 136 to 138
- Publications: details revised at 2 of 2 entries
- Minor Trial sites expanded: 133 → 136 locationsv26
- Minor Trial sites expanded: 125 → 132 locationsv25
- Minor Study sites: 125 to 132v24
- Minor Trial sites expanded: 115 → 125 locationsv23
- Minor Trial sites expanded: 112 → 115 locationsv22
- Minor Study sites: 111 to 112v21
- Minor Study sites: 110 to 111v20
- Minor Study sites: 109 to 110v19
- Minor Trial sites expanded: 103 → 107 locationsv18
- Minor Study sites: 103 to 107v17
- Minor Study sites: 102 to 103v16
- Minor Trial sites expanded: 99 → 102 locationsv15
- Minor Study sites: 100 to 99v14
- Minor Trial sites expanded: 96 → 100 locationsv13
- Minor Trial sites expanded: 78 → 96 locationsv12
- Minor Trial sites expanded: 71 → 78 locationsv11
- Minor Study sites: 68 to 71v10
- Minor Study sites: 53 to 68v9
- Minor Study sites: 50 to 53v8
- Minor Study sites: 44 to 50v7
- Minor Study sites: 28 to 44v6
- Minor Study sites: 16 to 28v5
- Minor Study sites: 5 to 16v4
- Minor Study sites: 3 to 5
- Start date changed from estimate of Jul 2025 to Jul 23, 2025
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 3
- Primary completion date: Apr 2029 to Oct 2029
- Study completion date: Jun 2029 to Dec 2029
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Total number of major adverse cardiovascular events (MACE) after coronary or peripheral endovascular revascularization
Timeframe: From randomization to first occurrence of MACE (up to approximately 4 years)
Total number of major adverse limb events (MALE) after endovascular revascularization
Timeframe: From randomization to first occurrence of MALE (up to approximately 4 years)
Secondary (3)
Number of participants with cardiovascular (CV) death
Number of participants with all cause death
Number of participants with venous thromboembolic events (VTE)
Arms and interventions
Inclisiran SodiumActive comparator
Inclisiran sodium 300 mg subcutaneous injection
PlaceboPlacebo comparator
Normal saline 1.5 ml subcutaneous injection
Drugs: Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Normal Saline (Placebo)
Sites
153 sites in 1 country